FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2025 BURLINGTON, Mass. , July 25, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to[…]

BURLINGTON, Mass. , May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]

Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million , despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents o f  $58.4 million Company to host investor conference call and webcast today, Tuesday, May 14 ,[…]

BURLINGTON, Mass. , May 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]

Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass. , May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care,[…]

FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass. , April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc.[…]

Generated 4Q 2023 net FUROSCIX ® revenue of $6.1 million , at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year net FUROSCIX ® revenue of $13.6 million , at the upper end of the range provided in January Ended[…]

Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass. , March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient[…]

BURLINGTON, Mass. , Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]

Company anticipates Q4 2023 net FUROSCIX   revenue to be approximately $5.9 to $6.1 million ; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million Gross-to-net (GTN) discount of approximately 18% from launch through the end of Q4 Inventory levels at the end of Q4 2023 consistent[…]